BIOMAT Database Logo BIOMAT Database Logo

Lansoprazole elevates the ratio of serum pepsinogen I v.s. pepsinogen II. 1997

Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.

In order to investigate the mechanism by which proton pump inhibitor increases serum pepsinogen levels, we evaluated the effects of ulcer location and IgG antibody against Helicobacter pylori on lansoprazole-induced elevations. Patients with endoscopically proven peptic ulcer received lansoprazole 30 mg/day for 6 or 8 weeks; pepsinogen I and II levels, along with antibody to H. pylori, were measured in fasting blood samples. We found that whether or not antibody to H. pylori was present, pepsinogen I and II levels and the I/II ratio rose significantly in lansoprazole-treated patients. Patients with stomach-body ulcers showed smaller increases in both pepsinogens than did those with ulcers in the gastric angle/antrum or in the duodenum. In conclusion, lansoprazole increases serum levels of both pepsinogens I and II, although a larger increase in pepsinogen I elevates the pepsinogen I/II ratio. The relatively small increases seen in patients with stomach-body ulcers suggest atrophic changes in the gastric mucosa in patients with stomach-body ulcer.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D010435 Pepsinogens Proenzymes secreted by chief cells, mucous neck cells, and pyloric gland cells, which are converted into pepsin in the presence of gastric acid or pepsin itself. (Dorland, 28th ed) In humans there are 2 related pepsinogen systems: PEPSINOGEN A (formerly pepsinogen I or pepsinogen) and PEPSINOGEN C (formerly pepsinogen II or progastricsin). Pepsinogen B is the name of a pepsinogen from pigs. Pepsinogen B
D010437 Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Gastroduodenal Ulcer,Marginal Ulcer,Gastroduodenal Ulcers,Marginal Ulcers,Peptic Ulcers,Ulcer, Gastroduodenal,Ulcer, Marginal,Ulcer, Peptic,Ulcers, Gastroduodenal,Ulcers, Marginal,Ulcers, Peptic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer
D016480 Helicobacter pylori A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405). Campylobacter pylori,Campylobacter pylori subsp. pylori,Campylobacter pyloridis,Helicobacter nemestrinae

Related Publications

Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
[Serum pepsinogen I/II ratio test].
January 2003, Nihon rinsho. Japanese journal of clinical medicine,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
[Pepsinogen I, pepsinogen II, and pepsinogen I/II ratio].
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
[Pepsinogen I and pepsinogen II, PG I/II ratio].
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
Pepsinogen I and II and the ratio pepsinogen I/II in detecting atrophic gastritis.
July 2009, Acta medica Indonesiana,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
Serum pepsinogen I and pepsinogen II, and the ratio of pepsinogen I/pepsinogen II in peptic ulcer diseases: with special emphasis on the influence of the location of the ulcer crater.
January 1995, Journal of gastroenterology and hepatology,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
Only serum pepsinogen I and pepsinogen I/II ratio are specific and sensitive biomarkers for screening of gastric cancer.
May 2019, Biomolecular concepts,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
Role of Serum Pepsinogen I and II Ratio in Screening of Gastric Carcinoma.
July 2017, Mymensingh medical journal : MMJ,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
[Effects of pepsinogen C gene polymorphisms on serum pepsinogen I and serum pepsinogen II levels].
February 1995, Nihon eiseigaku zasshi. Japanese journal of hygiene,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions.
January 2013, Asian Pacific journal of cancer prevention : APJCP,
Y Matsukawa, and S Nishinarita, and M Kaneko, and M Takei, and M Murakami, and T Horie, and F Kawamura, and Y Arakawa, and H Kuwayama, and H Kurosaka
[Changes of serum pepsinogen I/II ratio induced by Helicobacter pylori infection in hypertensive patients].
July 2014, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Copied contents to your clipboard!